Australia's most trusted
source of pharma news
Wednesday, 06 May 2026
Posted 6 May 2026 AM
Just as Melbourne-based Arovella was celebrating its transition into a clinical stage company after a major win with the FDA, it's been hit with a leadership spill instigated by a major shareholder.
This week the CEO and Managing Director has resigned along with three Board Directors.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.